Hepatitis B virus surface protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways

Abstract The protein inhibitor of activated STAT1 (PIAS1) plays important roles in regulating virus-induced chronic hepatitis, but the interaction between hepatitis B virus (HBV) and hPIAS1 is not clear. Our aim was to verify if HBV encoding proteins enhance the transcription of hPIAS1 and which cis-elements and transcription factors were involved in the mechanism. In order to do, so a series of molecular biological methods, along with functional and histological studies, were performed. We found that the HBV surface protein (HBs) enhanced hPIAS1 transcription through the activities of TAL1, E47, myogenin (MYOG), and NFI, dependent on the activation of p38MAPK and ERK signaling pathways in vitro, which might contribute to the ineffectiveness of treatment in CHB patients. Furthermore, liver samples from patients with high HBsAg levels and HBV DNA displayed increased hPIAS1 expression and high levels of TAL1, E47, MYOG, and NFI, compared to those patients with low HBsAg levels and HBV DNA, and healthy controls. These findings suggest that the HBs protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways. It provides new potential targets for antiviral therapeutic strategies for controlling HBV-associated diseases.

[1]  D. Murray,et al.  Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. , 2016, Leukemia research.

[2]  Y. Shyr,et al.  Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias. , 2015, Leukemia research.

[3]  Pinar Ozkal-Baydin How did hepatitis B virus effect the host genome in the last decade? , 2014, World journal of hepatology.

[4]  H. Mollenkopf,et al.  Pathological Impact of Hepatitis B Virus Surface Proteins on the Liver Is Associated with the Host Genetic Background , 2014, PloS one.

[5]  Jun Zhang,et al.  PIAS1 negatively modulates virus triggered type I IFN signaling by blocking the DNA binding activity of IRF3. , 2013, Antiviral research.

[6]  Y. Liaw,et al.  Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels , 2013, Hepatology.

[7]  J. Chen,et al.  [Hepatitis B surface antigen affects the expression of lipid metabolism-related genes in HepG2 cells]. , 2013, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[8]  M. Heikenwalder,et al.  Direct Effects of Hepatitis B Virus-Encoded Proteins and Chronic Infection in Liver Cancer Development , 2013, Digestive Diseases.

[9]  Y. L. Ma,et al.  NMDA receptor signaling mediates the expression of protein inhibitor of activated STAT1 (PIAS1) in rat hippocampus , 2013, Neuropharmacology.

[10]  J. V. van Dissel,et al.  Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β. , 2013, Cytokine.

[11]  H. Salem,et al.  The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[12]  Subrata Ghosh A Journey with the Journal , 2013 .

[13]  G. Raimondo,et al.  Hepatocellular carcinoma: the point of view of the hepatitis B virus. , 2011, Carcinogenesis.

[14]  C. Boucher,et al.  Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.

[15]  Kook Hwan Kim,et al.  Hepatitis B Virus X Protein Impairs Hepatic Insulin Signaling Through Degradation of IRS1 and Induction of SOCS3 , 2010, PloS one.

[16]  W. Liu,et al.  Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. , 2010, Antiviral research.

[17]  Zhan-qing Zhang,et al.  HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. , 2009, Molecular immunology.

[18]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[19]  Wei Guo,et al.  Hepatitis B Virus-induced hFGL2 Transcription Is Dependent on c-Ets-2 and MAPK Signal Pathway* , 2008, Journal of Biological Chemistry.

[20]  V. Chongsuvivatwong,et al.  Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. , 2008, World journal of gastroenterology.

[21]  E. Baixeras,et al.  Liver expression of proteins controlling interferon‐mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection , 2007, The Journal of pathology.

[22]  V. Deleuze,et al.  TAL-1/SCL and Its Partners E47 and LMO2 Up-Regulate VE-Cadherin Expression in Endothelial Cells , 2007, Molecular and Cellular Biology.

[23]  Y. Chawla,et al.  Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator on Treatment of Chronic Hepatitis B , 2007, The American Journal of Gastroenterology.

[24]  M. Nassal,et al.  Inhibition of Alpha Interferon Signaling by Hepatitis B Virus , 2006, Journal of Virology.

[25]  M. Campbell Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BLau GKK, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (Univ of Hong Kong, China; et al) N Engl J Med 352:2682–2695, 2005§ , 2006 .

[26]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[27]  Hong Wu,et al.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity , 2004, Nature Immunology.

[28]  M. Rudnicki,et al.  Cellular and molecular regulation of muscle regeneration. , 2004, Physiological reviews.

[29]  N. La Monica,et al.  Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. , 2004, Gastroenterology.

[30]  T. Hoang,et al.  SCL: from the origin of hematopoiesis to stem cells and leukemia. , 2004, Experimental hematology.

[31]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[32]  P. Duerksen-Hughes,et al.  Protein kinases and their involvement in the cellular responses to genotoxic stress. , 2003, Mutation research.

[33]  R. Gronostajski,et al.  Roles of the NFI/CTF gene family in transcription and development. , 2000, Gene.

[34]  C. Bréchot,et al.  Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. , 1999, The Journal of general virology.

[35]  D. Chang,et al.  Inhibition of Stat1-mediated gene activation by PIAS1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Peschle,et al.  Chromatin immunoselection defines a TAL‐1 target gene , 1998, The EMBO journal.

[37]  M. Chen,et al.  The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. , 1998, Journal of immunology.

[38]  P Jay,et al.  Specific inhibition of Stat3 signal transduction by PIAS3. , 1997, Science.

[39]  F. Zoulim,et al.  Heterogeneity of hepatitis B virus (HBV) core gene in a patient with HBV-associated cirrhosis and serum negativity for anti-HBc. , 1996, Journal of hepatology.

[40]  G. Fattovich,et al.  Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis , 1996 .

[41]  R. Kingston,et al.  Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins , 1994, Molecular and cellular biology.

[42]  S. Iino [Interferon therapy of chronic hepatitis]. , 1992, Nihon rinsho. Japanese journal of clinical medicine.

[43]  T. Tokino,et al.  Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. , 1990, Molecular biology & medicine.

[44]  Robert Tjian,et al.  A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication , 1987, Cell.

[45]  J. Hurwitz,et al.  Adenovirus DNA replication in vitro: identification of a host factor that stimulates synthesis of the preterminal protein-dCMP complex. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Saito Interferon therapy in chronic hepatitis B. , 1976, Lancet.